Neoponcirin (Mixture of diastereomers)

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: Neoponcirin (Mixture of diastereomers)
• 英文别名: 5-hydroxy-2-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
• 化学式: C₂₈H₃₄O₁₄
• 分子量: 594.6
• InChiKey: RMCRQBAILCLJGU-SMCKTMTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  214
• 氢给体数：
  7
• 氢受体数：
  14

文献信息

• Novel use of flavones
  申请人：——

  公开号：US20010046963A1

  公开（公告）日：2001-11-29

  A pharmaceutical composition for inhibiting COX- 2 biosynthesis comprising a therapeutically effective amount of the compound of formula I and a pharmaceutrically acceptable carrier. 1 wherein R 1 and R 4 represent either Hydrogen or together a bond R 5 , R 6 , R 7 , R 8 represent independently of each other Hydrogen, Hydroxy or Methoxy; in addition R 7 represents a sugar substituent like glucoside, rutinosid, manno gluco pyransyl, aprosylglucoside R 2 and R 3 represent Hydrogen, Hydroxy, Methoxy or 2 wherein R 2 ′, R 3 ′, R 4 ′, R 5 ′ and R 6 ′ are independently or each other Hydrogen, Hydroxy or Methoxy with the proviso, that R 2 or R 3 is represented by the optionally substituted Phenylring.

  一种用于抑制COX-2生物合成的药物组合物，包括化合物I的治疗有效量和药用可接受的载体。 其中R1和R4代表氢或一起表示键 R5、R6、R7、R8分别独立地表示氢、羟基或甲氧基；此外，R7表示糖取代物，如葡萄糖苷、鲁丁苷、甘露葡糖吡喃基、阿普罗西糖苷 R2和R3表示氢、羟基、甲氧基或 其中R2'、R3'、R4'、R5'和R6' 分别或彼此独立地表示氢、羟基或甲氧基，条件是R2或R3由可选择取代的苯环表示。
• [EN] COMPOUNDS EFFECTIVE IN TREATING HEPATOTOXICITY AND FATTY LIVER DISEASES AND USES THEREOF<br/>[FR] COMPOSÉS EFFICACES POUR TRAITER L'HÉPATOTOXICITÉ ET DES STÉATOSES HÉPATIQUES, ET UTILISATIONS DE CEUX-CI
  申请人：SINEW PHARMA INC

  公开号：WO2017050298A1

  公开（公告）日：2017-03-30

  The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof.

  本发明涉及用于治疗肝毒性和脂肪肝疾病的化合物及其用途。
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• Process for isolating phenolic compounds
  申请人：——

  公开号：US20030139610A1

  公开（公告）日：2003-07-24

  The invention provides compositions and methods for isolating phenolic compounds, particularly isoflavones, from aqueous extracts of plant materials that contain such compounds. The process comprising: (a) providing an aqueous plant extract at a first pH less than 10, the aqueous plant extract comprising a plurality of phenolic compounds; (b) extracting the aqueous plant extract with a first organic solvent to yield a first organic extract; (c) extracting the first organic extract with an aqueous phase of pH greater than 10 to yield a phenol rich aqueous phase; (d) adjusting the pH of the phenol rich aqueous phase to a pH of less than 9; and (e) isolating the phenolic compounds from the phenol rich aqueous phase.

  本发明提供了一种从含有这些化合物的植物材料的水提取物中分离酚类化合物，特别是异黄酮的组合物和方法。该过程包括：(a)在第一个pH小于10的条件下提供水性植物提取物，该水性植物提取物包含多种酚类化合物；(b)用第一个有机溶剂提取水性植物提取物，以得到第一个有机提取物；(c)用pH大于10的水相提取第一个有机提取物，以得到富含酚类的水相；(d)将富含酚类的水相的pH值调整为小于9的pH值；(e)从富含酚类的水相中分离酚类化合物。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。